Vaccine Marketing - Innovation and Marketing in the Pharmaceutical Industry - page 415

Ruijs WL, Hautvast JL, van der Velden K, de Vos S, Knippenberg H, Hulscher ME (2011)
Religious subgroups infl uencing vaccination coverage in the Dutch bible belt: an ecological
study. BMC Public Health 11:102
Sahoo A (2010) Vaccines 2010: the world market. Kalorama Information, New York, NY
Salmon DA, Moulton LH, Omer SB, DeHart MP, Stokley S, Halsey NA (2005) Factors associated
with refusal of childhood vaccines among parents of school-aged children: a case-control
study. Arch Pediatr Adolesc Med 159(5):470-476
Salmon DA, Teret SP, MacIntyre CR, Salisbury D, Burgess MA, Halsey NA (2006) Compulsory
vaccination and conscientious or philosophical exemptions: past, present, and future. Lancet
367(9508):436-442
Salmon DA, Pan WK, Omer SB, Navar AM, Orenstein W, Marcuse EK et al (2008) Vaccine
knowledge and practices of primary care providers of exempt vs. vaccinated children. Hum
Vaccin 4(4):286-291
Sandberg T, Conner M (2008) Anticipated regret as an additional predictor in the theory of planned
behaviour: a meta-analysis. Br J Soc Psychol 47(4):589-606
Sanofi Pasteur (2009) Vaccine IR seminar, 17th December 2009. http://en.sanofi .com/
Images/16351_090817_IR_Seminar_Vaccines.pdf . Accessed 18 Jan 2012
Saxenian H, Cornejo S, Thorien K, Hecht R, Schwalbe N (2011) An analysis of how the GAVI
alliance and low- and middle-income countries can share costs of new vaccines. Health Aff
30(6):1122-1133
Schaffer SJ, Humiston SG, Shone LP, Averhoff FM, Szilagyi PG (2001) Adolescent immunization
practices: a national survey of US physicians. Arch Pediatr Adolesc Med 155(5):566-571
Scherer FM (2007) An industrial organization perspective on the infl uenza vaccine shortage.
Manage Decis Econ 28(4):393-405
Schönberger K, Grote V, von Kries R, Kalies H (2009) Risikofaktoren für eine verspätete oder
nicht erfolgte Masernimpfung bei Kleinkindern. Bundesgesundheitsblatt Gesundheitsforschung
Gesundheitsschutz 52(11):1045-1051
Schoub BD, Ngcobo NJ, Madhi S (2010) The national advisory group on immunization (NAGI) of
the republic of South Africa. Vaccine 28(Suppl 1):A31-A34
Schwartz JL (2010) HPV vaccination's second act: promotion, competition, and compulsion. Am
J Public Health 100(10):1841-1844
Senouci K, Blau J, Nyambat B, Coumba Faye P, Gautier L, Da Silva A et al (2010) The supporting
independent immunization and vaccine advisory committees (SIVAC) initiative: a country-driven,
multi-partner program to support evidence-based decision making. Vaccine 28:A26-A30
Setse RW, Euler GL, Gonzalez-Feliciano AG, Bryan LN, Furlow C, Weinbaum CM, Singleton JA
(2011) Infl uenza vaccination coverage—United States, 2000-2010. Surveillance summaries:
morbidity and mortality weekly report. Surveillance Summaries/CDC 60(Suppl), 38-41.
Shearer JC, Stack ML, Richmond MR, Bear AP, Hajjeh RA, Bishai DM (2010) Accelerating pol-
icy decisions to adopt haemophilus infl uenzae type B vaccine: a global, multivariable analysis.
PLoS Med 7(3):e1000249
Shefer A, Markowitz L, Deeks S, Tam T, Irwin K, Garland SM et al (2008) Early experience with
human papillomavirus vaccine introduction in the United States, Canada and Australia. Vaccine
26(Suppl 10):K68-K75
Shen AK, Hunsaker J, Gazmararian JA, Lindley MC, Birkhead GS (2009a) Role of health insur-
ance in fi nancing vaccinations for children and adolescents in the United States. Pediatrics
124(Suppl 5):S522-S531
Shen AK, Rodewald LE, Birkhead GS (2009b) Perspective of vaccine manufacturers on fi nancing
pediatric and adolescent vaccines in the United States. Pediatrics 124(Suppl 5):S540-S547
Shirvill J (2010) Innovations and opportunities in therapeutic vaccines. Business Insights Ltd.,
Dundee
Shortridge EF, Moore JR, Whitmore H, O'Grady MJ, Shen AK (2011) Policy implications of fi rst-
dollar coverage: a qualitative examination from the payer perspective. Public Health Rep
126(3):394-399
Silverman E (2009) The vaccine market grows up: they're not just for kids anymore. IN VIVO, July